Journal of Ophthalmology, Год журнала: 2024, Номер 2024(1)
Опубликована: Янв. 1, 2024
To investigate the efficacy and safety of orthokeratology (ortho-k) repeated low-level red-light (RLRL) therapy in treating poor responders ortho-k myopic children.
Язык: Английский
Ophthalmic and Physiological Optics, Год журнала: 2024, Номер 44(2), С. 241 - 248
Опубликована: Янв. 5, 2024
Low-level red light (LLRL) therapy has recently emerged as a myopia treatment in children, with several studies reporting significant reduction axial elongation and progression. The goal of this study was to characterise the output determine thermal photochemical maximum permissible exposure (MPE) LLRL devices for control.
Язык: Английский
Процитировано
30
Ophthalmology, Год журнала: 2024, Номер 131(11), С. 1314 - 1323
Опубликована: Июнь 6, 2024
Язык: Английский
Процитировано
16
Ophthalmic and Physiological Optics, Год журнала: 2024, Номер 44(2), С. 270 - 279
Опубликована: Янв. 9, 2024
Abstract Purpose To review the rebound effect after cessation of different myopia control treatments. Methods A systematic that included full‐length randomised controlled studies (RCTs), as well post‐hoc analyses RCTs reporting new findings on treatments in two databases, PubMed and Web Science, was performed according to PRISMA statement. The search period between 15 June 2023 30 2023. Cochrane risk bias tool used analyse quality selected studies. Results total 11 were this review. Unifying effects all treatments, mean for axial length (AL) spherical equivalent refraction (SER) 0.10 ± 0.07 mm [−0.02 0.22] −0.27 0.2 D [−0.71 −0.03] 10.2 7.4 months washout, respectively. In addition, spectacles with highly aspherical lenslets or defocus incorporated multiple segments technology, soft multifocal contact lenses orthokeratology showed lower compared atropine low‐level light therapy, a AL SER 0.04 [0 0.08] −0.13 [−0.05 −0.2], Conclusions It appears produce their cessation. Specifically, optical seem less than pharmacological therapies. However, more are required confirm these results.
Язык: Английский
Процитировано
13
British Journal of Ophthalmology, Год журнала: 2024, Номер unknown, С. bjo - 323887
Опубликована: Май 22, 2024
Myopia has long been a global threat to public health. Timely interventions are likely reduce the risk of vision-threatening complications. There both established and rapidly evolving therapeutic approaches slow myopia progression and/or delay its onset. The effective methods for slowing include atropine eye-drops, defocus incorporated multiple segments (DIMS) spectacle lenses, lenses with highly aspherical lenslets target (HALT), diffusion optics technology (DOT) red light therapy (RLT), multifocal soft contact orthokeratology. Among these, 0.05% atropine, HALT RLT +3.00 peripheral addition yield over 60% reduction in progression, whereas DIMS, DOT MiSight demonstrate at least 50% control efficacy. demonstrates more optimal balance efficacy safety than 0.01%. 0.01% not consistent requires further validation across diverse ethnicities. Combining orthokeratology or DIMS spectacles yields better outcomes using these as monotherapies. Increased outdoor time is an health strategy prevention while recent studies suggest that low-concentration have promising potential clinical high-risk groups. being invasive, safe long-term use. However, when considering other approaches, it essential ensure proper instruction regular follow-ups maintain monitor any Ultimately, significant advances made strategies, many which shown meaningful outcomes. use adequate monitoring extended durations imperative foster confidence can only come from extensive experience.
Язык: Английский
Процитировано
12
JAMA Ophthalmology, Год журнала: 2024, Номер 142(6), С. 560 - 560
Опубликована: Апрель 25, 2024
Importance Treatments are needed to slow progression of or reduce incidence myopia. Objective To evaluate the efficacy and safety daily 650-nm low-level red light (LLRL) for myopia treatment. Design, Setting, Participants Single-masked, randomized clinical trial at 1 site in China. Baseline measurements were completed from August September 2021. children aged 6 12 years with spherical equivalent error (SER) −6 diopters (D) 3 D. Data analyzed March July 2023. Interventions Irradiation LLRL minutes twice 4 more hours apart no intervention. Main Outcomes Measures Primary outcomes changes cycloplegia SER axial length (AL) 6- 12-month follow-up visits. Safety was assessed on masked fundus photograph evaluations. Results A total 336 randomly allocated into group control a 1:1 ratio. The contained 86 female patients (51.2%), treatment 90 (53.6%). mean (SD) age, SER, AL 9.0 (1.9) years, −1.3 (1.5) D, 23.8 (1.0) mm all patients. 161 (95.8%) 159 (94.6%) returned 6-month follow-up. 157 (93.5%) 152 (90.5%) Mean 0.15 (0.16) D −0.26 (0.21) group, respectively (difference, −0.41 D; 95% CI, −0.48 −0.34 P < .001), months 0.24 (0.27) −0.65 (0.33) −0.89 −0.95 −0.83 months. −0.06 (0.08) 0.13 (0.12) 0.19 mm; 0.16 0.22 −0.11 (0.10) 0.26 0.37 0.34 0.40 .001). Masked review did not identify retinal either group. Conclusions relevance These findings suggest use year can without concerns identified. Confirmation these independent sites seems warranted, as well determining whether effects be sustained continued has any effect pathological Trial Registration ChiCTR2200058963
Язык: Английский
Процитировано
11
Photodiagnosis and Photodynamic Therapy, Год журнала: 2024, Номер 47, С. 104198 - 104198
Опубликована: Май 8, 2024
To investigate the safety of repetitive low-level red-light therapy (RLRLT) in children with myopia.
Язык: Английский
Процитировано
10
JAMA Ophthalmology, Год журнала: 2025, Номер unknown
Опубликована: Янв. 23, 2025
This Viewpoint discusses the ophthalmic device, red light therapy, for myopia treatment in children and adolescents China, including its development use, safety concerns, implications surrounding recent regulatory changes reclassification of this device.
Язык: Английский
Процитировано
1
Asia-Pacific Journal of Ophthalmology, Год журнала: 2025, Номер unknown, С. 100161 - 100161
Опубликована: Янв. 1, 2025
Myopia stands as a prevalent ocular condition with global implications, impacting individuals at various life stages. In school-age children and adolescents, uncorrected myopia impedes reading academic performance. Among middle-aged elderly populations, poses severe risks such macular degeneration, holes retinal detachment, leading to irreversible visual impairment. The term "myopia management" is widely embraced by ophthalmic practitioners optometry associations worldwide, encompassing strategies correct refractive errors ongoing assessment of disease progression, aiming reduce the progression axial elongation. To date, current management for include public health policies, optical solutions, medical interventions surgical options, but these are general lack age specificity. Despite existing interventions, we propose concept "Whole Life Cycle Management" in this review. This approach outlined major risk factors through whole cycle, discussed provided age-specific eight different stages-infancies, toddlers, preschoolers, children, young adults, middle-age old-age, including prevention onset, slowing monitoring complications. Achieving requires collaborations efforts from government, schools, hospitals families, restore vision enhance quality those affected myopia.
Язык: Английский
Процитировано
1
JAMA Ophthalmology, Год журнала: 2025, Номер unknown
Опубликована: Апрель 24, 2025
Importance Repeated low-level red light (RLRL) therapy has emerged as a potential intervention for controlling myopia progression in children. However, its long-term effects on retinal photoreceptors remain relatively unknown. Objective To evaluate changes associated with RLRL cone photoreceptor density children using high-resolution adaptive optics scanning laser ophthalmoscopy (AOSLO). Design, Setting, and Participants This retrospective multicenter cohort study analyzed data collected from January to March 2024, focusing Chinese myopia. All participants were recruited through questionnaires. Cone measurements obtained AOSLO images. Children aged 5 14 years the pediatric ophthalmology clinic during routine eye examinations included assigned group or control group. Inclusion criteria spherical equivalent refraction below −6.00 diopters (D) best-corrected visual acuity ≥20/20. Exposures measurement Main Outcomes Measures was measured along 4 meridians central fovea 4° eccentricity AOSLO. Fundus abnormalities assessed AOSLO, optical coherence tomography (OCT), fundus photography. Image evaluators masked allocation. Results A total of 99 this analysis: 52 (97 eyes; mean [SD] age, 10.3 [1.9] years; 27 female [51.9%]) 47 (74 9.8 [2.1] 25 male [53.2%]) users showed decreased within 0.5-mm foveal center, most notably temporal region. At 0.3-mm eccentricity, difference −2.1 × 10 3 cells/mm 2 compared controls (95% CI, −3.68 −0.59 ; P = .003). 11 eyes exhibited abnormal low-frequency, high-brightness signals near fovea. The odds ratio nonusers 7.23 1.15-303.45; Fisher exact test, .02). One participant had small cystoid OCT ganglion cell layer, which resolved months after discontinuing therapy. Conclusions Relevance suggest that at least 1 year reduced paracentral other subtle some receiving control. These findings support need further research longer-term safety similar individuals.
Язык: Английский
Процитировано
1
Journal of Clinical Medicine, Год журнала: 2024, Номер 13(5), С. 1506 - 1506
Опубликована: Март 5, 2024
Background: Early-onset myopia increases the risk of irreversible high myopia. Methods: This study systematically evaluated efficacy and safety low-dose atropine for control in children with premyopia through meta-analysis using random-effects models. Effect sizes were calculated ratios (RRs) 95% confidence intervals (CIs). Comprehensive searches PubMed, EMBASE, Cochrane CENTRAL, ClinicalTrials.gov conducted until 20 December 2023, without language restrictions. Results: Four studies involving 644 aged 4–12 years identified, concentrations ranging from 0.01% to 0.05%. The analysis focused on incidence atropine-related adverse events. Lower (RR, 0.62; CI, 0.40–0.97 D/y; p = 0.03) reduction rapid shift (≥0.5 D/1y) 0.50; 0.26–0.96 < 0.01) observed 12–24-month period. Spherical equivalent axial length exhibited attenuated progression group. No major events detected either group, whereas photophobia allergic conjunctivitis did not vary Conclusions: Our supports atropine’s delaying controlling premyopia. However, further investigation is warranted due limited studies.
Язык: Английский
Процитировано
9